Company: ARMP
Filing Date: 2025-08-20
Form Type: CORRESP
Source: 0001104659-25-080910
Chunk: 0

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-20
Form: CORRESP
Chunk 0
---
August 20, 2025

VIA EDGAR SUBMISSION

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, DC 20549

| Re: | Armata Pharmaceuticals, Inc. (the “Company”)             
 Registration Statement on Form S-3 (File No. 333-289585) 
 (the “Registration Statement”)                           |

Dear Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities
Act of 1933, as amended (the “Securities Act”), the Company hereby requests that the Securities and Exchange Commission (the
“Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective
on Friday, August 22, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

If you have any questions regarding this request,
please contact our outside counsel, Andrew C. Marmer of Willkie Farr & Gallagher LLP, at (212)-728-8847 or the undersigned at
(310)-626-0538. Please also call Andrew C. Marmer as soon as the Company’s Registration Statement on Form S-3 has been declared
effective. Thank you for your attention to this matter.

| Sincerely,                                                            |                 |
| ARMATA PHARMACEUTICALS, INC.                                          |                 |
| By:                                                                   | /s/ David House |
| Name: David House                                                     |                 |
| Title: Senior Vice President, Finance and Principal Financial Officer |                 |

cc: Andrew C. Marmer, Willkie Farr &
Gallagher LLP